MA55351A - Nouveaux composés pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de protéine tau - Google Patents
Nouveaux composés pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de protéine tauInfo
- Publication number
- MA55351A MA55351A MA055351A MA55351A MA55351A MA 55351 A MA55351 A MA 55351A MA 055351 A MA055351 A MA 055351A MA 55351 A MA55351 A MA 55351A MA 55351 A MA55351 A MA 55351A
- Authority
- MA
- Morocco
- Prior art keywords
- relief
- prevention
- treatment
- novel compounds
- disorders associated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 102000013498 tau Proteins Human genes 0.000 title 1
- 108010026424 tau Proteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19160275 | 2019-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55351A true MA55351A (fr) | 2022-01-26 |
Family
ID=65657372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055351A MA55351A (fr) | 2019-03-01 | 2020-01-29 | Nouveaux composés pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de protéine tau |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220127263A1 (fr) |
| EP (1) | EP3941477A1 (fr) |
| JP (1) | JP7232931B2 (fr) |
| CN (1) | CN113453688A (fr) |
| AR (1) | AR118141A1 (fr) |
| CA (1) | CA3131805C (fr) |
| MA (1) | MA55351A (fr) |
| TW (1) | TW202100525A (fr) |
| WO (1) | WO2020177952A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR123730A1 (es) * | 2020-10-15 | 2023-01-04 | Ac Immune Sa | Compuestos novedosos |
| WO2023025109A1 (fr) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | Inhibiteur du récepteur de type toll et sa préparation et son application |
| EP4644396A1 (fr) * | 2022-12-28 | 2025-11-05 | Visionpharma (Nantong) Co., Ltd | Inhibiteur de récepteur de type toll, sa préparation et son application |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008264D0 (en) * | 2000-04-04 | 2000-05-24 | Smithkline Beecham Plc | Novel method and compounds |
| WO2004058239A1 (fr) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| WO2007096743A1 (fr) * | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Quinazolines substituées en tant qu'inhibiteurs de pde10 |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| WO2010053127A1 (fr) * | 2008-11-05 | 2010-05-14 | 協和発酵キリン株式会社 | Modulateur du récepteur α1-gabaa ou du récepteur α5-gabaa |
| AU2009336040B2 (en) | 2008-12-18 | 2015-07-16 | Merck Patent Gmbh | Tricyclic azaindoles |
| AU2011239966B2 (en) * | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| CA2829223A1 (fr) * | 2011-03-11 | 2012-09-20 | Beka Solomon | Methode de traitement de tauopathie neurodegenerative |
| CN107556267A (zh) * | 2016-06-30 | 2018-01-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型噻唑衍生物类化合物、其制备方法、药物组合物及其制药用途 |
| SG11202005607WA (en) * | 2018-01-05 | 2020-07-29 | Ac Immune Sa | 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease |
| US11684625B2 (en) * | 2018-06-04 | 2023-06-27 | Ac Immune Sa | Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates |
-
2020
- 2020-01-29 EP EP20701485.3A patent/EP3941477A1/fr not_active Withdrawn
- 2020-01-29 US US17/434,918 patent/US20220127263A1/en not_active Abandoned
- 2020-01-29 WO PCT/EP2020/052088 patent/WO2020177952A1/fr not_active Ceased
- 2020-01-29 JP JP2021549761A patent/JP7232931B2/ja active Active
- 2020-01-29 CA CA3131805A patent/CA3131805C/fr active Active
- 2020-01-29 MA MA055351A patent/MA55351A/fr unknown
- 2020-01-29 CN CN202080017958.5A patent/CN113453688A/zh active Pending
- 2020-02-19 AR ARP200100457A patent/AR118141A1/es not_active Application Discontinuation
- 2020-02-20 TW TW109105551A patent/TW202100525A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220127263A1 (en) | 2022-04-28 |
| EP3941477A1 (fr) | 2022-01-26 |
| JP2022521968A (ja) | 2022-04-13 |
| TW202100525A (zh) | 2021-01-01 |
| CA3131805C (fr) | 2023-11-21 |
| JP7232931B2 (ja) | 2023-03-03 |
| CA3131805A1 (fr) | 2020-09-10 |
| CN113453688A (zh) | 2021-09-28 |
| AR118141A1 (es) | 2021-09-22 |
| WO2020177952A1 (fr) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51520A (fr) | Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer | |
| EP3914604A4 (fr) | Compositions et procédés pour traiter, prévenir ou inverser une inflammation et des troubles associés à l'âge | |
| EP3837359A4 (fr) | Méthodes et compositions pour le traitement d'une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie | |
| MA46018A (fr) | Activateurs d'édition du génome | |
| EP3870170A4 (fr) | Méthodes et compositions pour le traitement de la presbytie, de la mydriase et d'autres troubles oculaires | |
| MA51673A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| EP3411380A4 (fr) | Composés destinés au traitement de troubles ou de maladies oculaires | |
| EP3504204A4 (fr) | Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie | |
| EP3934646A4 (fr) | Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires | |
| EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
| MA52616A (fr) | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| EP4081201A4 (fr) | Composition pharmaceutique pour le traitement ou la prévention de nombreux troubles inflammatoires | |
| EA202092557A1 (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА | |
| MA55497A (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP3943107A4 (fr) | Composition pour prévenir ou traiter une maladie du cerveau et du système nerveux | |
| MA56114A (fr) | Composés pour le traitement de troubles dépendant de la kinase | |
| EP3936124A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement de maladies neurologiques | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| EP4021480A4 (fr) | Peptides pour le traitement de troubles rénaux | |
| EP3710015A4 (fr) | Utilisation d'agents srsf3 pour le traitement et/ou la prévention d'affections neurologiques, du cancer, d'infections bactériennes ou d'infections virales | |
| MA51679A (fr) | Composés destinés au traitement de troubles dépendant de la kinase | |
| EP3996729C0 (fr) | Composition pour la prévention ou le traitement de la dépression ou de l'anxiété | |
| EP4181915A4 (fr) | Compositions pour le traitement de l'obésité |